From GlobeNewswire: 2025-03-18 16:05:00

Absci Corporation reported financial results for Q4 and full year 2024, showcasing progress in AI platform and drug creation. Highlights include collaborations with AMD, Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center. Cash reserves are sufficient until H1 2027. Revenue for Q4 was $0.7 million, R&D expenses increased to $18.4 million, and net loss was $29 million. Full year revenue was $4.5 million, R&D expenses were $63.9 million, and net loss was $103.1 million. Cash, cash equivalents, and short-term investments as of December 31, 2024, were $112.4 million.



Read more at GlobeNewswire:: Absci Reports Business Updates and Fourth Quarter and Full